Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Enterprise Value history runs 14 years deep, the most recent figure standing at -$762.2 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 19.72% year-over-year to -$762.2 million in Q1 2026; TTM through Mar 2026 was -$762.2 million, a 19.72% decrease from a year earlier, with the FY2025 full-year figure at -$874.7 million, down 21.89% from the prior year.
• Enterprise Value rose to -$762.2 million in Q1 2026 per VRDN's latest filing, from -$874.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$161.2 million in Q2 2022 and bottomed at -$874.7 million in Q4 2025.
• The 5-year median for Enterprise Value is -$490.9 million (2025), against an average of -$510.2 million.
• Across the five-year window, Enterprise Value plunged 140.65% in 2024 and jumped 34.83% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$424.6 million in 2022, then fell by 12.44% to -$477.4 million in 2023, then plunged by 50.32% to -$717.6 million in 2024, then dropped by 21.89% to -$874.7 million in 2025, then rose by 12.86% to -$762.2 million in 2026.
• Per Business Quant, the three latest VRDN Enterprise Value figures stand at -$762.2 million (Q1 2026), -$874.7 million (Q4 2025), and -$490.9 million (Q3 2025).